189 related articles for article (PubMed ID: 37227919)
1. BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.
Shu X; Li J; Chan UI; Su SM; Shi C; Zhang X; An T; Xu J; Mo L; Liu J; Wang Y; Li X; Deng M; Lei JH; Wang C; Tian H; Heng S; Shim JS; Zhang X; Dai Y; Yao Z; Kuang X; Lin Y; Deng CX; Xu X
Cancer Res; 2023 Aug; 83(15):2614-2633. PubMed ID: 37227919
[TBL] [Abstract][Full Text] [Related]
2. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy.
Li J; Shu X; Xu J; Su SM; Chan UI; Mo L; Liu J; Zhang X; Adhav R; Chen Q; Wang Y; An T; Zhang X; Lyu X; Li X; Lei JH; Miao K; Sun H; Xing F; Zhang A; Deng C; Xu X
Nat Commun; 2022 Mar; 13(1):1481. PubMed ID: 35304461
[TBL] [Abstract][Full Text] [Related]
3. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
Martinez-Outschoorn UE; Balliet R; Lin Z; Whitaker-Menezes D; Birbe RC; Bombonati A; Pavlides S; Lamb R; Sneddon S; Howell A; Sotgia F; Lisanti MP
Cell Cycle; 2012 Dec; 11(23):4402-13. PubMed ID: 23172369
[TBL] [Abstract][Full Text] [Related]
5. Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4.
Ma X; Dong W; Su Z; Zhao L; Miao Y; Li N; Zhou H; Jia L
Cell Death Dis; 2016 Dec; 7(12):e2561. PubMed ID: 28032858
[TBL] [Abstract][Full Text] [Related]
6. iPSC-Derived Hereditary Breast Cancer Model Reveals the
Portier L; Desterke C; Chaker D; Oudrhiri N; Asgarova A; Dkhissi F; Turhan AG; Bennaceur-Griscelli A; Griscelli F
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513753
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
Bai F; Chan HL; Scott A; Smith MD; Fan C; Herschkowitz JI; Perou CM; Livingstone AS; Robbins DJ; Capobianco AJ; Pei XH
Cancer Res; 2014 Nov; 74(21):6161-72. PubMed ID: 25239453
[TBL] [Abstract][Full Text] [Related]
8. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
9. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
Sami E; Paul BT; Koziol JA; ElShamy WM
Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
12. Identification and functional characterization of a human GalNAc [alpha]2,6-sialyltransferase with altered expression in breast cancer.
Sotiropoulou G; Kono M; Anisowicz A; Stenman G; Tsuji S; Sager R
Mol Med; 2002 Jan; 8(1):42-55. PubMed ID: 11984005
[TBL] [Abstract][Full Text] [Related]
13. AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.
Kubli SP; Bassi C; Roux C; Wakeham A; Göbl C; Zhou W; Jafari SM; Snow B; Jones L; Palomero L; Thu KL; Cassetta L; Soong D; Berger T; Ramachandran P; Baniasadi SP; Duncan G; Lindzen M; Yarden Y; Herranz C; Lazaro C; Chu MF; Haight J; Tinto P; Silvester J; Cescon DW; Petit A; Pettersson S; Pollard JW; Mak TW; Pujana MA; Cappello P; Gorrini C
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3604-3613. PubMed ID: 30733286
[TBL] [Abstract][Full Text] [Related]
14. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
15. Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway.
Bai F; Wang C; Liu X; Hollern D; Liu S; Fan C; Liu C; Ren S; Herschkowitz JI; Zhu WG; Pei XH
Cell Death Dis; 2022 Mar; 13(3):195. PubMed ID: 35236825
[TBL] [Abstract][Full Text] [Related]
16. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density.
Tamburini BAJ; Elder AM; Finlon JM; Winter AB; Wessells VM; Borges VF; Lyons TR
Front Immunol; 2019; 10():1313. PubMed ID: 31244852
[TBL] [Abstract][Full Text] [Related]
18. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
[TBL] [Abstract][Full Text] [Related]
19. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
[TBL] [Abstract][Full Text] [Related]
20. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
